Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?

Gold, Bert; Cankovic, Milena; Furtado, Larissa V.; Meier, Frederick A.; Gocke, Christopher D.

doi:10.1016/j.jmoldx.2015.02.001

Cited by 184 publications

(161 citation statements)

References 199 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…EVs offer an attractive pathway providing both minimally invasive diagnostics as well as longitudinal therapeutic response metrics of cancer. This approach involves EVs from blood for cancers of lung, breast and leukaemia; from urine for prostate cancer diagnosis and rejection metrics for renal allografts; and cerebrospinal fluid (CSF) for glioblastoma and Alzheimer’s disease [10,11]. …”

Section: Significance and Innovationmentioning

confidence: 99%

Extracellular vesicles: the growth as diagnostics and therapeutics; a survey

Roy

Hochberg

Jones

2018

J of Extracellular Vesicle

118

View full text Add to dashboard Cite

This article aims to document the growth in extracellular vesicle (EV) research. Here, we report the growth in EV-related studies, patents, and grants as well as emerging companies with major intent on exosomes. Four different databases were utilized for electronic searches of published literature: two general databases – Scopus/Elsevier and Web of Science (WoS), as well as two specialized US government databases – the USA Patent and Trademark Office and National Institutes of Health (NIH) of the Department of Health and Human Services. The applied combination of key words was carefully chosen to cover the most commonly used terms in titles of publications, patents and grants dealing with conceptual areas of EVs. Within the time frame from 1 January 2000 to 31 December 2016, limited to articles published in English, we identified output using search strategies based upon Scopus/Elsevier and WoS, patent filings and NIH Federal Reports of funded grants. Consistently, USA and UK universities are the most frequent among the top 15 affiliations/organizations of the authors of the identified records. There is clear evidence of upward streaming of EV-related publications. By documenting the growth of the EV field, we hope to encourage a roster of independent authorities skilled to provide peer review of manuscripts, evaluation of grant applications, support of foundation initiatives and corporate long-term planning. It is important to encourage EV research to further identify biomarkers in diseases and allow for the development of adequate diagnostic tools that could distinguish disease subpopulations and enable personalized treatment of patients.

show abstract

Section: Significance and Innovationmentioning

confidence: 99%

Extracellular vesicles: the growth as diagnostics and therapeutics; a survey

Roy

Hochberg

Jones

2018

J of Extracellular Vesicle

118

View full text Add to dashboard Cite

show abstract

“…However, for CTCs to realize their potential, important limitations of sequencing data from single cells must be understood and addressed. 4 The first is ensuring that the CTC identification methods used discriminate CTCs from other circulating cells with high specificity. This high specificity is required for successful adoption of CTCs as a realistic alternative to traditional biopsies.…”

Section: Discussionmentioning

confidence: 99%

“…3,4 The enumeration of CTCs using the CellSearch platform currently has Food and Drug Administration approval as an adjunctive prognostic marker during therapy in many solid cancers. 5 The development of CTC assays that allow for the capture and isolation of CTCs for further analysis has the potential to transform CTCs into a liquid biopsy for cancers.…”

mentioning

confidence: 99%

Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer

Court

Ankeny

Sho

et al. 2016

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

To understand the potential and limitations of circulating tumor cell (CTC) sequencing for molecular diagnostics, we investigated the feasibility of identifying the ubiquitous KRAS mutation in single CTCs from pancreatic cancer (PC) patients. We used the NanoVelcro/laser capture microdissection CTC platform, combined with whole genome amplification and KRAS Sanger sequencing. We assessed both KRAS codon-12 coverage and the degree that allele dropout during whole genome amplification affected the detection of KRAS mutations from single CTCs. We isolated 385 single cells, 163 from PC cell lines and 222 from the blood of 12 PC patients, and obtained KRAS sequence coverage in 218 of 385 single cells (56.6%). For PC cell lines with known KRAS mutations, single mutations were detected in 67% of homozygous cells but only 37.4% of heterozygous single cells, demonstrating that both coverage and allele dropout are important causes of mutation detection failure from single cells. We could detect KRAS mutations in CTCs from 11 of 12 patients (92%) and 33 of 119 single CTCs sequenced, resulting in a KRAS mutation detection rate of 27.7%. Importantly, KRAS mutations were never found in the 103 white blood cells sequenced. Sequencing of groups of cells containing between 1 and 100 cells determined that at least 10 CTCs are likely required to reliably assess KRAS mutation status from CTCs. (J Mol Diagn 2016, 18: 688e696; http://dx

show abstract

“…6(1), 1482-1491 1483 advances in molecular and cancer pathology. Particularly the use of cell free nuclei acid in the plasma as tumor markers [7,8,9]. The present work was based on studying the expression of genes and microRNAs that are the cause or the result of lung cancer formation, namely P53 [10,11], KRAS [12], c-MYC [13], Her-2/neu [14], microRNAs-21 [16,17], 34a [18], 92 [19], and 98 [20] genes in the plasma of patient diagnosed as cancer and benign lung diseases in order to obtain a discrimination score for differentiating malignant from benign lung conditions.…”

Section: Issn: 2320-5407mentioning

confidence: 99%

Discriminant Score (D Score) a Model to Predict Lung Cancer Based on the Expression Study of Panel of Genes and Micrornas in the Plasma.

Aljebori.¹,

ChB²

2018

IJAR

View full text Add to dashboard Cite

Background: Lung cancer is the leading cause of death from cancer worldwide in adult, and accounting for (13%) of all newly diagnosed cancer cases. Inspite of that there is no effective method for screening of highly susceptible groups such as chronic heavy smokers. The present study depends on expression of panel of genes and microRNAs that are involved or the result of lung cancer formation in blood samples taken from cancer and non-cancer lung cases to design a discrimination score that can exclude or predict lung cancer. Objective: Is to design a discrimination score (D score) to predict lung cancer in blood samples based of expression study of a panel of genes and microRNAs. Patients and Method: A case control study on expression of P53, KRAS, c-MYC, and Her-2/neu genes, microRNAs 21, 34a, 92, and 98 in blood samples taken from patients positive and negative for lung cancer. Results: The discrimination score (D score) was obtained per a mathematical equation for each sample. According to the value of discrimination score:any new case with a discrimination score (D score) more than 0.0 is considered as a lung cancer and the higher the result the more we are confident the case is lung cancer. Any case with discrimination score below 0.0 is considered as a benign lung condition, and the lower the result the more we are confident the case is a benign condition.

show abstract

Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?

Cited by 184 publications

References 199 publications

Extracellular vesicles: the growth as diagnostics and therapeutics; a survey

Extracellular vesicles: the growth as diagnostics and therapeutics; a survey

Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer

Discriminant Score (D Score) a Model to Predict Lung Cancer Based on the Expression Study of Panel of Genes and Micrornas in the Plasma.

Contact Info

Product

Resources

About